Background: Elevated homocysteine (hcy) levels are associated with dementia, which is a frequent nonmotor symptom of Parkinson's disease (PD). High levels of hcy in PD patients treated with levodopa are thought to result from increased synthesis during the metabolism of levodopa by COMT, and that use of a COMT-inhibitor may reduce hcy levels. In this study, we sought to clarify the effects of COMT-inhibitors on dementia in PD patients. Methods: Thirty-eight PD patients without dementia (PDwoD), 35 PD patients with dementia (PDD), and 48 controls were enrolled in this study. All subjects underwent neuropsychological testing and a neurological examination. The hcy levels were measured in all subjects, and the relationship between hcy levels and dementia was evaluated in two PD groups (those that underwent treatment with levodopa-alone versus treatment with levodopa plus a COMT-inhibitor). Results: Patients in the PDD group showed higher hcy levels than patients in the PDwoD group, though there was no significant difference in the hcy level between PDwoD patients and healthy controls. Regarding the effects of a COMT-inhibitor, there was no correlation between hcy levels in the 2 PD subgroups, indicating that there were no significant effects of the COMT-inhibitor on PDD. In addition, the odds ratio for PDD with the use of a COMT-inhibitor was 0.864 (95% CI= 0.342-2.180). Conclusions: These results are in agreement with previous studies in that levodopa treatment in PD patients leads to elevated hcy concentrations. COMT-inhibitors, on the other hand, had no preventive effect on cognitive impairment in PD patients.
INTRODUCTION
Dementia is a frequent manifestation of advanced Parkinson' s disease (PD) [1] . The incidence of dementia in patients with PD is 2-6 times higher than in the general population, and increases with disease duration [2] . The exact cause and underlying neurological mechanism behind the development of dementia in PD are still unknown. Serum hcy has various neuronal and endothelial cellular toxicities, and hyperhomocysteinemia is associated with cardiovascular, ocular, cerebrovascular, and neurodegenerative disease [1, 3] . Elevated hcy levels have also been reported to correlate with depression, mild cognitive impairment, and dementia in the elderly population, and hcy levels have been found to predict rates of cognitive decline in healthy elderly individuals [4, 5] . Therefore, elevated serum hcy levels have been implicated in the pathogenesis of cognitive impairment such as vascular dementia and Alzheimer' s disease [5, 6] .
Levodopa is the most efficacious and well-tolerated drug for the treatment of patients with PD [7] , though it has been shown to lead to increased serum homocysteine (hcy) levels [1] . This is due to the O-methylation of levodopa, which is catalyzed by the enzyme catechol-O-methyltransferase (CO-MT) and requires S-adenosylmethionine (SAM) as the methyl donor for the production of S-adenosylhomocysteine (SAH), which is rapidly hydrolyzed to hcy. This chronic increase in hcy synthesis exceeds the capacity of cells to metabolize hcy, leading to elevated serum hcy levels [8] . Serum hcy levels in patients with PD treated with levodopa are specifically thought to be elevated due to increased synthesis from the metabolism of levodopa by COMT [1, 4, 8] . A previous animal study demonstrated that pre-treatment with a COMT inhibitor can block the elevation of serum hcy levels when levodopa is given [9] . These findings suggest that a COMT inhibitor such as Effect of COMT-inhibitor on PDD 137 entacapone may reduce levodopa-induced elevations in serum hcy levels in patients with PD. Despite these findings, it is unclear whether hyperhomocysteinemia in PD patients is related to cognitive decline. Furthermore, little work has been done to assess the effects of COMT inhibitors on dementia in PD patients.
Therefore, in this study we sought to determine whether COMT inhibitors were able to block elevations in serum hcy levels in PD patients, and consequently reduce the occurrence of dementia.
METHODS
This study was approved by the local ethics committee, and each patient gave written informed consent prior to partici- were collected from all subjects in tubes containing ethylenediaminetetraacetic acid. The samples were immediately separated by centrifugation at 3,000 rpm for 10 min. The separated sera were stored at -70°C until the laboratory evaluation.
La boratory data were collected by an examiner whom was blind ed to clinical details and patient information.
All PD patients were additionally categorized into two groups including those treated with levodopa alone (group 1) or levodopa and a COMT inhibitor (group 2). All patients in group 2 took entacapone 600 mg/day from the time that PD was diagnosed.
Statistical analysis was performed using an SPSS software PD, we determined the odds ratio by using binary logistic regression analysis. P-values< 0.05 were considered to be statistically significant.
RESULTS
The demographic characteristics of all subjects are summarized in Table 1 . There were no overall significant differences in age or gender distribution between PD patients and healthy controls, though PDD patients were significantly older than PDwoD patients and healthy controls. Additionally, the duration of disease and symptoms in the PDD versus PDwoD groups were significantly different, though there were no differences in daily levodopa doses between these groups.
Serum hcy levels were greater in the PDD group than the PDwoD group, but there was no difference between the PDwoD and the healthy control subjects.
Regarding the effects of the COMT-inhibitor, no correlation was found between serum hcy levels in groups 1 and 2.
In addition, there was no difference in the number of PDD patients between groups 1 and 2. Group 2 did, however, show a longer duration of treatment and greater severity of motor symptoms than group 1 (Table 2) . Furthermore, binary logis- tic regression analysis showed that the odds ratio for PDD with the use of a COMT-inhibitor was 0.864 (95% CI= 0.342-2.180).
DISCUSSION
It is well documented that older age, longer duration of disease, and greater severity of symptoms are associated with dementia in cases of advanced PD [4, 6, 13] . In this study, we also found that PDD is more strongly associated with older age and longer duration of disease than PDwoD. It has been proposed that elevated hcy levels in levodopa-treated PD may be caused by levodopa treatment rather than by the disease itself [2, 13] . Thus, elevated hcy has been identified as a risk factor for dementia. It is also known that elevated hcy levels lead to the acceleration of diseases such as atherosclerosis, neurodegeneration, and dementia [14] , and that cerebrovascular diseases and cognitive impairment worsen the prognosis of patients with PD [4, 14] . Taken together, these studies suggest that elevated hcy levels in PD patients are correlated with cognitive impairment including dementia. Our data confirmed these findings, in that serum hcy levels in patients with PDD were higher than those with PDwoD. Furthermore, PDD patients had a longer duration of PD levodopa treatment than PDwoD patients.
While COMT-inhibitors are used currently in the treatment of PD, recent studies have also discussed the potential use of a COMT-inhibitor such as entacapone to decrease hcy concentrations [9, 15, 16] . This hypothesis is based on the idea that inhibition of peripheral COMT would not only improve the bioavailability of levodopa due to a decrease in peripheral de gradation, but also lower the hcy levels [9, 15] . Consequently, a lower hcy level could lead to improvement in cognitive impairment in PD patients. On the contrary, however, the present study showed no relationship between hcy levels and CO MT-inhibitor use. Furthermore, we did not find any correlation between administration of a COMT-inhibitor and the occurrence of dementia in PD patients (odds ratio = 0.864, 95% CI= 0.342-2.180). Therefore we could cautiously assume that pretreatment with a COMT-inhibitor in PD patients did not prevent the effects of levodopa on hcy levels or the occurrence of dementia in PD patients.
In conclusion, our findings agree with previous studies in that levodopa treatment in PD patients results in elevated hcy concentrations. We also found, however, that a COMT-inhibitor did not prevent cognitive impairment in PD patients.
Therefore, future large-scale longitudinal studies are needed to further clarify the effects of COMT-inhibitors on dementia and the relationship between COMT-inhibitors and hcy concentrations in patients with PD.
